日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension

多纳内单抗治疗早期症状性阿尔茨海默病：TRAILBLAZER-ALZ 2 长期扩展研究的结果

期刊:Jpad-Journal of Prevention of Alzheimers Disease
影响因子:7.8
doi:10.1016/j.tjpad.2025.100446
Zimmer, Jennifer A; Sims, John R; Evans, Cynthia D; Nery, Emel Serap Monkul; Wang, Hong; Wessels, Alette M; Tronchin, Giulia; Sato, Shoichiro; Raket, Lars Lau; Andersen, Scott W; Sapin, Christophe; Paget, Marie-Ange; Gueorguieva, Ivelina; Ardayfio, Paul; Khanna, Rashna; Brooks, Dawn A; Matthews, Brandy R; Mintun, Mark A
TRAIL
阿尔茨海默症
发表日期：2026
文献求助 收藏

Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's disease

接受多纳单抗治疗的早期症状性阿尔茨海默病患者出现输注相关反应

期刊:Alzheimer's and Dementia: Translational Research and Clinical Interventions
影响因子:6.8
doi:10.1002/trc2.70229
Ardayfio, Paul; Mullins, Garrett R; Khanna, Rashna; Zimmer, Jennifer A; Wang, Hong; Nery, Emel Serap Monkul; Evans, Cynthia D; Piela, Pawel; Battioui, Chakib; Lauzon, Steve; Anglin, Greg; Ng, Hui Wen; Jayaraman, Anu Rita; Agada, Noah; Natalie, Chitra R; Brooks, Dawn A; Sims, John R
阿尔茨海默症
发表日期：2026
文献求助 收藏

Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials

多纳内单抗治疗早期症状性阿尔茨海默病患者的淀粉样蛋白相关影像学异常：TRAILBLAZER-ALZ 和 ALZ 2 随机临床试验的二次分析

期刊:Jama Neurology
影响因子:21.3
doi:10.1001/jamaneurol.2025.0065
Zimmer, Jennifer A; Ardayfio, Paul; Wang, Hong; Khanna, Rashna; Evans, Cynthia D; Lu, Ming; Sparks, JonDavid; Andersen, Scott; Lauzon, Steve; Nery, Emel Serap Monkul; Battioui, Chakib; Engle, Staci E; Biffi, Alessandro; Svaldi, Diana; Salloway, Stephen; Greenberg, Steven M; Sperling, Reisa A; Mintun, Mark; Brooks, Dawn A; Sims, John R
TRAIL
阿尔茨海默症
发表日期：2025
文献求助 收藏

Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction

改良的多纳单抗滴定方案可降低 ARIA 风险并维持淀粉样蛋白减少。

期刊:Alzheimers & Dementia
影响因子:11.1
doi:10.1002/alz.70062
Wang, Hong; Serap Monkul Nery, Emel; Ardayfio, Paul; Khanna, Rashna; Otero Svaldi, Diana; Gueorguieva, Ivelina; Shcherbinin, Sergey; Andersen, Scott W; Hauck, Paula M; Engle, Staci E; Brooks, Dawn A; Collins, Emily C; Fox, Nick C; Greenberg, Steven M; Salloway, Stephen; Mintun, Mark A; Sims, John R
发表日期：2025
文献求助 收藏

Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease

多纳内单抗在早期症状性阿尔茨海默病患者中的免疫原性

期刊:Alzheimer's and Dementia: Translational Research and Clinical Interventions
影响因子:6.8
doi:10.1002/trc2.70149
Mullins, Garrett R; Ardayfio, Paul; Gueorguieva, Ivelina; Anglin, Greg; Bailey, Jason; Chua, Laiyi; Zimmer, Jennifer A; Evans, Cynthia D; Nery, Emel Serap Monkul; Wang, Hong; Khanna, Rashna; Brooks, Dawn A; Sims, John R
阿尔茨海默症
免疫/内分泌
发表日期：2025
文献求助 收藏

Genome-wide association studies reveal genetic control of nutritional quality, milling traits, and agronomic characteristics in oat (Avena sativa L.)

全基因组关联研究揭示了燕麦（Avena sativa L.）营养品质、制粉性状和农艺特性的遗传控制。

期刊:Plant Genome
影响因子:3.8
doi:10.1002/tpg2.70060
Ardayfio, Naa Korkoi; Kinney, Christy; Li, Dandan; Naraghi, Sepehr Mohajeri; McMullen, Michael S; Fiedler, Jason D
发表日期：2025
文献求助 收藏

Using Clinical Scales and Digital Measures to Explore Falls in Patients with Lewy Body Dementia

利用临床量表和数字测量方法探索路易体痴呆患者的跌倒情况

期刊:Digital Biomarkers
影响因子:
doi:10.1159/000529623
Battioui, Chakib; Man, Albert; Pugh, Melissa; Wang, Jian; Dang, Xiangnan; Zhang, Hui; Ardayfio, Paul; Munsie, Leanne; Hake, Ann Marie; Biglan, Kevin
发表日期：2023
文献求助 收藏

Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial

美维达伦治疗路易体痴呆的安全性和有效性：一项 2 期随机、安慰剂对照试验

期刊:Movement Disorders
影响因子:7.6
doi:10.1002/mds.28879
Biglan, Kevin; Munsie, Leanne; Svensson, Kjell A; Ardayfio, Paul; Pugh, Melissa; Sims, John; Brys, Miroslaw
发表日期：2022
文献求助 收藏

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator, in Patients With Parkinson Disease

中枢性多巴胺D1受体正向变构调节剂Mevidalen (LY3154207)在帕金森病患者中的安全性、耐受性和药代动力学研究

期刊:Clinical Pharmacology in Drug Development
影响因子:1.8
doi:10.1002/cpdd.1039
Wilbraham, Darren; Biglan, Kevin M; Svensson, Kjell A; Tsai, Max; Pugh, Melissa; Ardayfio, Paul; Kielbasa, William
信号转导
帕金森
神经科学
发表日期：2022
文献求助 收藏

Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine

CENTURION 的安全性研究结果，这是一项评估拉斯米地坦用于急性治疗偏头痛的 3 期一致性研究

期刊:Journal of Headache and Pain
影响因子:7.9
doi:10.1186/s10194-021-01343-2
Tassorelli, C; Bragg, S; Krege, J H; Doty, E G; Ardayfio, P A; Ruff, D; Dowsett, S A; Schwedt, T
偏头痛
神经科学
发表日期：2021
文献求助 收藏